WFH Guidelines for the Management of Hemophilia
Hemophilia is a rare disorder that is complex to diagnose and manage. By compiling the second edition of its Guidelines for the Management of Hemophilia, the World Federation of Hemophilia (WFH) aims to provide practical, evidence-based guidance to healthcare providers, government authorities, and patient organizations seeking to initiate and/or maintain hemophilia care programs. It is also hoped these guidelines will encourage practice harmonization around the world and, where recommendations lack adequate evidence, stimulate appropriate studies.
The WFH guidelines have been endorsed by the International Society for Thrombosis and Haemostasis and are now available on the U.S. National Guideline Clearinghouse website.
Read a commentary on the guidelines, by Mike Makris and Carol Kasper, in Haemophilia.
Updates to the Guidelines for the Management of Hemophilia
This document tracks changes (2013) that have been made since the 2nd edition was first published in July 2012.
Click here to download the complete PDF, or select individual sections below.
Also available in:
The WFH recently endorsed the NHF-McMaster Guideline on Care Models for Hemophilia Management. Click here to view the full text of the guideline, published in the Journal of Haemophilia, June 27, 2016, or here to read the Executive Summary of the NHF-McMaster guideline.
Summary and introduction >
Section 1: General care and management of hemophilia >
||What is hemophilia?
||Principles of care
||Monitoring health status and outcome
||Fitness and physical activity
||Surgery and invasive procedures
||Dental care and management
||Prophylactic factor replacement therapy
Section 2: Special management issues >
||Genetic testing/counselling and prenatal diagnosis
||Delivery of infants with known or suspected hemophilia
||Ageing hemophilia patients
||Von Willebrand disease and rare bleeding disorders
Section 3: Laboratory Diagnosis >
||Knowledge and expertise in coagulation laboratory testing
||Use of the correct equipment and reagents
For detailed laboratory testing protocols, consult the WFH’s Diagnosis of Hemophilia and Other Bleeding Disorders.
Section 4: Hemostatic agents >
||Clotting factor concentrates
||Other plasma products
||Other pharmacological options
Section 5: Treatment of specific hemorrhages >
||Central nervous system
||Throat and neck hemorrhage
||Acute gastrointestinal hemorrhage
||Soft tissue hemorrhage
||Acute abdominal hemorrhage
||Lacerations and abrasions
Section 6: Complications of hemophilia >
||Transfusion-transmitted and other infection-related complications
Section 7: Plasma factor level and duration of administration
Appendix I: Oxford Centre for Evidence-Based Medicine, 2011 Levels of Evidence
Tables and Figures
Updated August 2014